These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26487583)

  • 1. Early market access of cancer drugs in the EU.
    Martinalbo J; Bowen D; Camarero J; Chapelin M; Démolis P; Foggi P; Jonsson B; Llinares J; Moreau A; O'Connor D; Oliveira J; Vamvakas S; Pignatti F
    Ann Oncol; 2016 Jan; 27(1):96-105. PubMed ID: 26487583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
    Leyens L; Brand A
    Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
    Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
    Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine.
    Leyens L; Richer É; Melien Ø; Ballensiefen W; Brand A
    Public Health Genomics; 2015; 18(5):249-59. PubMed ID: 26316202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rosian K; Wild C; Simon J
    Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations.
    Tarricone R; Banks H; Ciani O; Brouwer W; Drummond MF; Leidl R; Martelli N; Sampietro-Colom L; Taylor RS
    Expert Rev Med Devices; 2023 Apr; 20(4):259-271. PubMed ID: 36987818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
    Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
    ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
    Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
    Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
    [No Abstract]   [Full Text] [Related]  

  • 20. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
    Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
    Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.